All In Biotech

NDA 021402 · Abbvie

Synthroid

Levothyroxine Sodium · Oral

Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Jul 24, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

216

36 Phase 3, 17 recruiting

FAERS reports

284,278

170,196 serious, 18,736 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life - threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions ( 6 ), Drug Interactions ( 7.7 ), and Overdosage ( 10 )] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning . Thyroid hormones, including SYNTHROID , should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may...

What it is approved for

From the label in effect Feb 20, 2024.

Hypothyroidism SYNTHROID is indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid -Stimulating Hormone, TSH) Suppression SYNTHROID is indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism [see Warnings and Precautions ( 5.1 )]. SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. SYNTHROID is a L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. ( 1 ) Limitations of Use: Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis

Mechanism: Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 24, 2002 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLabelLetter
12 products under this application
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2
  • SYNTHROID · LEVOTHYROXINE SODIUM 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Levothyroxine" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue24,085
  • nausea20,602
  • drug ineffective19,511
  • headache17,631
  • diarrhoea17,282
  • dyspnoea15,417
  • pain15,291
  • dizziness14,190
  • off label use12,846
  • arthralgia12,369
  • asthenia12,079
  • malaise11,260

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045,676
20056,024
20066,271
20076,361
20088,196
20098,927
201011,698
201112,714
201215,040
20139,851
201411,106
201516,316
201616,838
201715,459
201815,047
201914,927
202017,224
202115,401
202216,286
202314,427
202414,155
202514,954
202611,372

Recalls

5 FDA enforcement reports for this application.

  • Oct 17, 2023 · Class III · Ongoing

    Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.

  • Dec 4, 2012 · Class II · Terminated

    Labeling: Error on Declared Strength. Product labeled to contain 150 mcg tablets actually contained 75 mcg tablets.

  • Jul 19, 2012 · Class II · Terminated

    Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

  • Jul 19, 2012 · Class II · Terminated

    Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

  • Jul 19, 2012 · Class II · Terminated

    Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Synthroid (Levothyroxine Sodium)

2024 spending

$348M

Beneficiaries

1,125,443

4,990,576 claims

Per beneficiary

$309

$0.99 per unit

View as table
YearSpending
2020$327,297,973
2021$343,569,697
2022$353,232,969
2023$355,295,646
2024$348,092,809

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 612 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.